Jobs
-
Seelos Therapeuticse has announced an additional amendment to its 2018 agreement with Vyera Pharmaceuticals (now Phoenixus) in order for the company to repurchase 9% of royalties payable on any future net sales of SLS-002 intranasal… Read more . . .
-
The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm’s Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a… Read more . . .
-
According to Altimmune, the FDA has now cleared the company’s IND for a Phase 1 trial of its AdCOVID intranasal vaccine candidate, and enrollment in the trial is expected to begin within a week. Altimmune… Read more . . .
-
The US Patent and Trademark Office has issued US Patent No. 10,874,818, titled “Aerosol Delivery System,” covering technology used in the delivery of Windtree Therapeutics’ Aerosurf aerosolized KL4 surfactant, Windtree said. The company redesigned the… Read more . . .
-
Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm).… Read more . . .
-
A Phase 2 study of inhaled budesonide for the treatment of COVID-19 found that patients who received 800 mcg twice daily plus standard of care within 7 days after first experiencing symptoms had a 90%… Read more . . .
-
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix’s PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary… Read more . . .
-
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics’ AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension… Read more . . .
-
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform’s biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics… Read more . . .
-
Hovione Technology, a subsidiary of CDMO Hovione, announced that it has been granted a patent on a new method of particle size analysis that provides improved sample preparation for more accurate measurements and better repeatability.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA